Marketing a med spa weight-loss program in 2026: GLP-1 advertising risks and compliant positioning
A med spa can market a medical weight-loss program, but in 2026 it has to sell the program, the clinical oversight and the support, not a cheaper copy of a brand-name drug. Since the FDA declared the semaglutide and tirzepatide shortages resolved, it has sent waves of warning letters over compounded GLP-1 advertising, and the FTC has acted against a telehealth weight-loss provider over pricing, fake reviews and weight-loss claims. This guide turns those actions into a checklist for your ads, website and front desk.
- The FDA resolved the semaglutide shortage on February 21, 2025; its enforcement discretion for compounders ended April 22, 2025 (503A) and May 22, 2025 (503B).
- FDA warning letters in September 2025 and March 2026 targeted claims that compounded GLP-1s are the same as, or as proven as, FDA-approved drugs.
- The FTC's 2025 case against a telehealth weight-loss firm shows the other risk: prices that hide drug, lab or visit costs, fake reviews and average-loss claims.
- Market a physician-led program: assessment, prescribing when appropriate, follow-up, nutrition and support. Not a drug at a price.
- Medical weight-loss clinics in our 20-metro benchmark had a median of 42 Google reviews, against 148 for med spas, so reviews are an open lane.
- Every practice welcome — retainers from $499/mo, Goals-Driven engagements, Performance-Linked Payout Models available.
- Dallas, Texas LLC
- 10-person US client team · Central Time (CST)
- 25+ US healthcare clients
- BAA signed with every client
- HIPAA compliance training across client and delivery teams
- Contracts and invoices in USD
-
Primary Care · North Dallas, TXCase study →
-
MedSpa · North Dallas, TX
-
Skin Care · Beverly Hills, CA
-
Dental · Christiansburg, VACase study →
-
Pediatrics · Blacksburg, VACase study →
-
Pediatric Dentistry · Blacksburg, VACase study →
-
Dental · Roanoke, VACase study →
-
Functional Medicine · Telehealth · USACase study →
“When I first approached Ichelon Consulting, my YouTube channel was stuck and despite my own efforts, it was not growing. They created a specific strategy which was based on SEO, and completely evaluating the channel, which worked great and has propelled our YouTube channel to new heights. Because of the channel growth, we have seen new patient consultations coming on a regular basis.”
What changed for GLP-1 advertising in 2025 and 2026
Short answer: the shortage that allowed widespread compounding ended, and regulators moved from tolerance to enforcement. Advertising that leaned on "same drug, lower price" is now the main target.
| Date | Action | What it means for your marketing |
|---|---|---|
| Dec 2024 – Feb 2025 | The FDA declared the tirzepatide shortage and then the semaglutide shortage (February 21, 2025) resolved. | The legal basis for mass compounding of copies of these drugs narrowed. |
| Apr 22 / May 22, 2025 | End of FDA enforcement discretion for semaglutide compounding by 503A pharmacies and 503B outsourcing facilities. | Ask your pharmacy partner, in writing, what they compound and under what authority. |
| Jul 2025 | The FTC acted against a telehealth weight-loss firm over misleading membership prices, fake and suppressed reviews and unsubstantiated weight-loss claims (final order December 2025). | Price disclosure, reviews and average-result claims are FTC issues, not just FDA issues. |
| Sep 9, 2025 | The FDA announced a crackdown on misleading drug advertising: thousands of letters and about 100 cease-and-desist letters, with warning letters to compounded GLP-1 sellers. | Digital and influencer promotion is in scope. |
| Feb 6, 2026 | The FDA said it intends to act against non-FDA-approved GLP-1 drugs mass-marketed as alternatives to approved drugs, including unsubstantiated claims. | "Alternative to [brand]" positioning is a red flag. |
| Mar 3, 2026 | The FDA warned 30 telehealth companies over compounded GLP-1 marketing, citing claims implying sameness with approved drugs and branding that obscures who compounds the product. | Don't brand a compounded product with your med spa's name as if you made it. |
The state-by-state compounding picture and pharmacy law are covered in our weight-loss clinic marketing compliance guide. This page focuses on what to change in your ads, site and front-desk scripts.
Claims to remove today
Short answer: anything that says or implies a compounded product is the same as, as safe as or as proven as an approved drug, and any price or result claim you can't back up.
Sameness claims
"Same active ingredient as [brand]", "generic [brand]", "[brand] at half the price", "clinically proven" for a compounded product. The FDA flagged these patterns in its warning letters.
Result claims
"Lose 20% of your body weight", "patients lose X pounds on average", unqualified before-and-after photos. The FTC requires substantiation, and testimonials must reflect typical results or disclose them.
Price claims
A headline monthly price that excludes the medication, labs, the prescribing visit or a minimum term. The FTC challenged exactly this in its 2025 case.
Also remove "FDA-approved" from anything that isn't, "no side effects", guarantees, and urgency tricks such as fake countdown timers. If you use influencers or staff accounts, the FTC Endorsement Guides apply; see our influencer endorsement guide.
Compliant positioning: sell the program, not the drug
Short answer: your advantage over online sellers is in-person medical care. Make that the product.
- Name the program, not the medicine. "Physician-led medical weight loss" or "Medical weight-loss program with monthly check-ins".
- Describe the process: assessment and labs, a provider deciding whether medication is appropriate, follow-up visits, nutrition and activity support, and a plan for maintenance.
- Say who is involved: the supervising physician and the prescribers, by name and credential. Supervision rules vary by state; see medical director requirements and ownership rules by state.
- Be honest about candidacy: not everyone is a candidate and the provider decides. That sentence protects you and builds trust.
- Talk about medication generally on your site ("If appropriate, your provider may prescribe an FDA-approved medication"), and leave product choice to the consultation.
- Disclose your sourcing honestly if you dispense anything: who makes it and whether it is FDA-approved.
Google, Meta and tracking
- Google Ads: prescription drug terms are restricted in US ads, keywords and landing pages, with certification paths for accredited pharmacies, telehealth providers and manufacturers. Build campaigns around "medical weight loss near me" and "weight loss doctor [city]". Our Google Ads healthcare policy guide and the LegitScript deep guide explain certification.
- Meta: weight-loss products and services must be targeted to people 18 and older, ads can't create negative self-perception, and prescription drug promotion needs LegitScript certification plus Meta authorization. See our Meta healthcare restrictions guide.
- Tracking: weight, BMI, medication and program enrollment should never reach an ad pixel. Use the setup in our HIPAA-safe website tracking guide.
- Texts and calls: check-in and promotional texts need the right consent. See the med spa TCPA guide.
Pricing disclosure and recurring programs
Short answer: if you show a price, show everything it does and doesn't include, right next to it. Recurring programs must also follow auto-renewal law.
- List what's included: initial consultation, labs, medication, follow-up visits, coaching.
- List what costs extra, and any minimum commitment, in the same place as the price.
- For monthly programs, get clear consent to recurring charges and offer a simple way to cancel. The FTC's 2024 click-to-cancel rule was vacated by a federal appeals court in July 2025, but the Restore Online Shoppers' Confidence Act (ROSCA) and state auto-renewal laws still apply.
- Never make refunds conditional on removing a review. The FTC's 2025 case alleged exactly that, and the FTC's reviews rule prohibits review suppression through threats or intimidation.
Membership design and retention are covered in our membership marketing guide, and the legal terms in the membership terms of service guide.
Reviews: where med spas can outcompete weight-loss clinics
Short answer: stand-alone weight-loss clinics have thin Google profiles. A med spa with steady, genuine reviews stands out.
| Google profile metric (20 US metros) | Medical weight loss (n=632) | Med spas (n=555) |
|---|---|---|
| Average rating | 4.79 | 4.87 |
| Median review count | 42 | 148 |
| Profiles with under 50 reviews | 53.8% | 15.9% |
| Open at least one weekend day | 48.4% | 74.2% |
Source: Ichelon Consulting US Google Business Profile benchmarks, 2026. Details in medical weight loss marketing statistics, the weight-loss Google benchmarks and med spa marketing statistics.
Ask every patient for an honest review once they've had a few follow-ups, without incentives and without asking only the happy ones. Reply to every review without confirming anyone is a patient or mentioning weight or medication. Our guide on HIPAA-safe review replies has examples.
More guides are in the US guides library and our research is in the US research library. See how we work or book a call.
What we found when we studied 555 US med spas on Google
Patients praise the care almost without exception. The one area where complaints outnumber praise is booking and communication, and that is where most med spas can win.
Full study · 555 US med spas across 20 metros · roughly ±4% nationally · review velocity and themes from a 115-spa subsample · verified against raw data.
Front desk and consultation scripts
Short answer: most compliance problems in weight-loss programs happen in conversations, not ads. Script the questions you get every day.
"Do you have [brand name]?"
"Our providers decide which medication, if any, is right for you after an assessment and labs. We'll explain the options and costs at your consultation."
"Is yours the same as [brand]?"
Answer accurately about what you prescribe or dispense and whether it is FDA-approved. Never say a compounded product is the same as, or a generic of, an approved drug.
"How much will I lose?"
"Results vary from person to person. Your provider will talk through realistic goals for you and how we track progress at each visit."
- Quote the full cost when asked: consultation, labs, medication, follow-ups and any minimum term.
- Keep clinical questions with providers. Front desk staff and social media managers shouldn't advise on dosing, side effects or suitability.
- Move health details out of DMs and public comments to your booking system or a provider call.
- Document the program in writing for each patient: what's included, how billing works and how to stop.
The same discipline applies to influencers and staff accounts that mention your program. Any perk is a material connection that must be disclosed, and the claims rules above apply to their posts as if they were your ads.
Sources
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA: Resolution of shortages of semaglutide injection products
- FDA: Resolution of tirzepatide injection product shortage
- FDA: FDA launches crackdown on deceptive drug advertising (September 2025)
- FDA: FDA intends to take action against non-FDA-approved GLP-1 drugs (February 2026)
- FDA: Warning to 30 telehealth companies over compounded GLP-1 marketing (March 2026)
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss
- FTC press release (July 2025): action against a telemedicine firm over GLP-1 program prices, fake reviews and weight-loss claims
- FTC press release (December 2025): final order in that case
- 16 CFR Part 465: FTC rule on consumer reviews and testimonials
- Eighth Circuit opinion vacating the FTC negative option rule (July 2025)
- Google Ads policy: Healthcare and medicines · Meta: Drugs and pharmaceuticals
Note: general marketing information, not legal advice. Compounding and prescribing rules change quickly and vary by state; confirm your program with healthcare counsel and your state medical and pharmacy boards.
Related pages from the US team
Weight-loss clinic marketing compliance 2026
State-by-state compounding, platform rules and off-label boundaries.
Weight loss clinic marketing (USA)
Our agency service page for weight-loss practices.
Medical weight loss marketing statistics
Google benchmarks for 632 US weight-loss clinics.
Body contouring marketing guide
Positioning shaping treatments for people near their goal weight.
Med spa membership marketing guide
Recurring programs, auto-renewal rules and retention.
Med spa marketing agency USA
How Ichelon Consulting US runs med spa marketing.
Every practice welcome — Goals-Driven engagements from $499/mo
We benchmark your last 90 days, agree monthly goals with you, and track them live on Ichelon Agency OS with a report every Monday. Performance-Linked Payout Models are available. Our US leadership is based in Dallas, and strategy calls run in US business hours.
Common questions
Can a med spa advertise compounded semaglutide or tirzepatide?
It is high risk. Compounded drugs are not FDA-approved, and the FDA has warned companies against claiming that compounded GLP-1s are the same as, generic versions of, or as clinically proven as approved drugs. Since the shortages were resolved, routine compounding of copies of approved drugs is also restricted. Many practices advertise their weight-loss program and leave medication choice to the provider consultation. Get legal advice on your specific situation.
Can we use Ozempic, Wegovy, Mounjaro or Zepbound in our ads?
Google restricts prescription drug terms in US ads, keywords and landing pages, and Meta limits prescription drug promotion to certified advertisers. Most med spas are not eligible, so brand names in ads are likely to be disapproved. Advertise the medical weight-loss program instead.
What did the FTC object to in its 2025 GLP-1 weight-loss case?
In July 2025 the FTC took action against a telehealth company selling GLP-1 weight-loss memberships, alleging that advertised monthly prices left out the cost of the drug, lab work and the prescribing consultation, that the company used fake and suppressed reviews and testimonials from non-customers, and that it made unsubstantiated average weight-loss claims. The final order was approved in December 2025.
How should a med spa show the price of a weight-loss program?
If you advertise a price, make clear what it includes and excludes: consultation, labs, medication, follow-up visits, minimum commitment and cancellation terms. If any of those cost extra, say so next to the price, not in fine print.
Can we post patient weight-loss testimonials?
Only genuine testimonials from real patients, with written authorization, and only if the results shown are typical or you clearly disclose what people can generally expect. The FTC's rule on consumer reviews and testimonials also bans fake reviews and buying positive ones.
Do HIPAA rules apply to weight-loss marketing?
If your practice is a HIPAA covered entity, weight, BMI, medications and program enrollment are protected health information. Keep them out of ad pixels and lead forms connected to ad platforms. Even if HIPAA does not apply, state health privacy laws and the FTC may.
A note on this guide: it explains marketing practice, not legal advice. Rules on privacy, advertising and insurance change and vary by state, so confirm anything compliance-related with your own counsel.
Running a weight-loss program inside your med spa?
Book a 30-minute benchmarking call. A member of our Sr. Leadership team will review your ads, pricing pages and reviews against the 2025 to 2026 enforcement actions.